



Medicine Supply Notification

MSN/2025/057

Mometasone (Asmanex Twisthaler®) 200micrograms/dose dry powder and 400micrograms/dose dry powder inhalers

Tier 2 – medium impact*

Date of issue: 20/10/2025

Link: [Medicines Supply Tool](#)

Summary

- Mometasone (Asmanex Twisthaler®) 200microgram/dose dry powder inhaler (60 dose) is being discontinued from late October 2025.
- Mometasone (Asmanex Twisthaler®) 200microgram/dose dry powder inhaler (30 dose) and 400micrograms/dose dry powder inhaler (30 dose and 60 dose) are being discontinued from late February 2026.
- Alternative corticosteroid inhalers remain available (see Supporting Information)

Actions Required

Prescribers should:

- not initiate new patients on Asmanex Twisthalers®;
- identify and review existing patients prescribed an Asmanex Twisthaler® and consider appropriateness of switching to another inhaled treatment in line with [NICE asthma guidelines](#) (see Supporting Information); and
- ensure that the patient is not intolerant to any of the excipients in the new inhaler, is counselled on how to use the inhaler if judged suitable for use, on the dose to be administered, and to seek advice from their prescriber if asthma worsens.

If the above options are not considered appropriate, advice should be sought from specialists on management options.

Supporting information

Clinical Information

Mometasone dry powder inhalers are licensed for the regular treatment of asthma in adults and children 12 years of age and older.

[NICE asthma guidelines](#) updated in 2024 recommend that the initial management for newly diagnosed asthma in people aged 12 years and over should now be with either:

- Low-dose inhaled corticosteroid/formoterol combination to be taken as-needed (Anti-inflammatory reliever [AIR] therapy); or

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

- Low-dose maintenance and reliever (MART) therapy for patients with highly symptomatic asthma (e.g. regular nocturnal waking) or with a severe exacerbation, which can be stepped down to as-needed AIR therapy, if asthma is controlled.

The [BNF](#) notes budesonide with formoterol is licensed for as-needed AIR therapy in mild asthma, and beclometasone with formoterol and budesonide with formoterol are licensed for MART.

[Links to further information](#)

[BNF Chronic asthma](#)

[NICE guidelines \[NG245\]: Asthma](#)

[SmPC Asmanex Twisthaler](#)

[SmPCs: Budesonide-Formoterol combination inhalers](#)

[SmPCs: Beclometasone- Formoterol combination inhalers](#)

[Right Breathe: Budesonide+ Formoterol inhalers](#)

[Right Breathe: Beclometasone + Formoterol inhalers](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.